Merck & Co., Inc: Bacterial Infections trials

The registry lists 12 Bacterial Infections studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 3Phase 2 2Phase 3 4Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)CompletedNCT02452047Phase 3Results posted
• A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)CompletedNCT01340937Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)CompletedNCT01337167Phase 3Results posted
• Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract SurgeryCompletedNCT00575380Phase 4Results posted
• Study of AzaSite Versus Vigamox in the Tears of Healthy VolunteersCompletedNCT00575367Phase 4Results posted
• Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy VolunteersCompletedNCT00564447Phase 4Results posted
• Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mgCompletedNCT01271998Phase 1
• Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent PatientsCompletedNCT01156077Phase 1
• Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)CompletedNCT00983255Phase 1
• A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)CompletedNCT00551915Phase 2
• A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)CompletedNCT00551629Phase 2
• Daptomycin for the Treatment of Infections Due to Gram-Positive BacteriaTerminatedNCT00055198Phase 3